<table>
<thead>
<tr>
<th>Subscription rates</th>
<th>1 year</th>
<th>2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual rate (1)</td>
<td>€130 (174 USD)</td>
<td>€240 (322 USD)</td>
</tr>
<tr>
<td>Student rate (1)</td>
<td>€60 (80 USD)</td>
<td>€112 (150 USD)</td>
</tr>
<tr>
<td>Institutional rate (1/2)</td>
<td>€325 (436 USD)</td>
<td>€630 (844 USD)</td>
</tr>
</tbody>
</table>

1- For Solidarity subscription rates see the preceding page.
2- Commercial companies and institutions.

Yes, I would like to subscribe to Prescrire International

Please send me a free sample issue of the French journal Prescrire

Title: Mr □ Ms □

Last Name: ____________________________

First Name: __________________________

Address (1): __________________________________________________________________________

City: __________________________

Country: __________________________

Tel: __________________________

Fax: __________________________

E-Mail (must be provided): __________________________

Occupation: ____________________________________________________________

1- Give the format of the address as it is used in your country.

I enclose a cheque for € __________________________
or USD __________________________

I pay € __________________________
or USD __________________________

by Credit card

Visa □

Eurocard/Mastercard □

American Express □

Card number: ____________ ____________ ____________ ____________

Expiry date: ____________ / ____________

Signature: __________________________________________

Send your order with payment to:
Prescrire International
83 bd Voltaire - 75558 PARIS CEDEX 11 - FRANCE
Fax: + 33 1 49237648
e-mail: international@prescrire.org
website: www.english.prescrire.org

Pharmacovigilance in Europe: some progress, but a missed opportunity

On 29 November 2010 the Council of the European Union approved the new European pharmacovigilance regulation and directive. Below are some points contained in a joint press release by Prescrire and its partners in a campaign to improve the originally dangerous proposals.

The European Commission’s original proposals were greatly improved. Thanks to the mobilisation of civil society and the numerous amendments adopted by the European Parliament’s Committee on Environment, Public Health and Food Safety (ENVI), improvements included:

– making clear that risk management systems must not be used as a pretext for granting premature marketing authorisations;
– giving patients in all Member States the right to report adverse drug reactions;
– having patients report adverse drug reactions to health authorities, rather than to pharmaceutical companies;
– granting public access to the agendas and detailed minutes of meetings of European Medicines Agency (EMA) committees.

However, Member States will no longer be required to provide public funding for pharmacovigilance systems, which will jeopardise the independence of pharmacovigilance systems.

A missed opportunity. If patient safety is to be truly strengthened in the EU, the following actions would be required:

– regulatory authorities should only grant authorisation for drugs that have been shown to provide a tangible therapeutic advantage for patients;
– a system should be set up to strongly encourage health professionals to systematically report the adverse effects they observe;
– drug regulatory authorities should be made more independent.

Dangerous medicines should not be allowed to continue harming patients and the proliferation of pharmacovigilance scandals (Vioxx°, Accomplia°, Avandia°, Mediator° etc.) must be stopped. We therefore call on the European Commission to rapidly propose more ambitious measures in order to reinforce patient safety.